Assembly Biosciences
ASMB
39 hedge funds and large institutions have $18M invested in Assembly Biosciences in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.43% less ownership
Funds ownership: 2.86% → 2.42% (-0.43%)
22% less funds holding
Funds holding: 50 → 39 (-11)
34% less capital invested
Capital invested by funds: $27.2M → $18M (-$9.19M)
47% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 19
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$315K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$116K |
| 3 |
Jane Street
New York
|
+$93.7K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$63.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$48.5K |
Top Sellers
ASMB Hedge Fund Activity: Q4 2022 in Review
39 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2022, worth a combined $18M — down 34% from $27.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ASMB and 1 opened new positions — a net loss of 11 holders — while 19 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $315K. The largest seller was Deep Track Capital, cutting an estimated $1.66M.
- 39 institutional investors held Assembly Biosciences (ASMB) as of Q4 2022, down from 50 in Q3 2022.
- Funds reported $18M of Assembly Biosciences stock for Q4 2022, down 34% quarter-over-quarter.
- 1 fund opened new Assembly Biosciences positions in Q4 2022 and 12 closed out, a net change of -11 holders.
- The largest Assembly Biosciences buyer in Q4 2022 was Renaissance Technologies, an estimated $315K added.
- The largest Assembly Biosciences seller in Q4 2022 was Deep Track Capital, an estimated $1.66M sold.
Based on aggregated 13F filings for Q4 2022.